4.5 Interaction with other medicinal products and other forms of interaction   
 No interaction studies have been performed.  
 In clinical trials, XGEVA has been administered in combination with standard anti -cancer treatment and in subjects previously receiving bisphosphonates. There were no clinically -relevant alterations in trough serum concentration and pharmacodynamics of denosumab (creatinine adjusted urinary N-telopeptide, u 
 NTX/Cr) by concomitant chemotherapy and/or hormone therapy or by previous intravenous bisphosphonate exposure.  
 
